Hulme Rachel, Wilkinson Owen, Haythornthwaite Ella, Benjamin Veronia, Matharu Hemali, Politis Marina, Womersley Kate, Norton Robyn, Witt Alice
The George Institute for Global Health UK, London, UK.
Imperial College London, London, UK.
BMJ Public Health. 2025 Jul 17;3(2):e002510. doi: 10.1136/bmjph-2024-002510. eCollection 2025.
The importance of sex and gender in the diagnosis and management of health conditions is well established, but the extent to which sex and gender disaggregated evidence is integrated into UK clinical practice guidelines remains unknown. Recent reviews of clinical guidelines in Canada and Europe identified that limited and inconsistent attention was paid to sex and gender dimensions of health and illness. This study aimed to determine how the UK's National Institute of Clinical Excellence (NICE) clinical guidelines account for sex and gender.
The study reviewed all NICE guidelines categorised as 'clinical guidelines' by NICE (223), excluding those solely linked to single-sex conditions (26). Reviewers evaluated whether they included information on sex and/or gender dimensions of disease risk, presentation, investigations and management. They also examined if sex and/or gender dimensions were considered outside of pregnancy, and how the gender of guideline committee chairs and members corresponded to how well sex and/or gender were accounted for.
Of 197 guidelines reviewed, 120 (61%) referenced sex and/or gender dimensions, with 81 (41%) referencing these dimensions outside of pregnancy and childbearing. A minority of guidelines mentioned sex and/or gender dimensions related to disease pathophysiology (2%), clinical presentation (9%), investigations (15%) and epidemiology (19%). 162 guidelines published details of their committee chairs, and 126 (76%) were men. Committees chaired by women tended to produce guidelines, which scored better for consideration of sex and gender.
This study highlights key gaps in NICE guidelines which must be addressed through systematic, whole-sector progress to integrate sex and gender disaggregated research into clinical guidelines. As the single focal point responsible for guideline development in England and Wales, NICE has a unique opportunity to establish robust mechanisms to routinely embed this important evidence in guidelines. Multiple initiatives are recommended to identify relevant existing evidence across all clinical specialties.
性别在健康状况的诊断和管理中的重要性已得到充分确立,但按性别分类的证据在英国临床实践指南中的整合程度仍不明确。最近对加拿大和欧洲临床指南的综述发现,对健康和疾病的性别维度关注有限且不一致。本研究旨在确定英国国家卫生与临床优化研究所(NICE)的临床指南如何考虑性别因素。
该研究回顾了NICE归类为“临床指南”的所有指南(共223份),不包括那些仅与单性别疾病相关的指南(26份)。评审人员评估这些指南是否包含有关疾病风险、表现、检查和管理的性别维度信息。他们还研究了在非孕期是否考虑了性别维度,以及指南委员会主席和成员的性别与性别因素的考虑程度之间的对应关系。
在审查的197份指南中,120份(61%)提及了性别维度,其中81份(41%)在非孕期和生育期之外提及了这些维度。少数指南提到了与疾病病理生理学(2%)、临床表现(9%)、检查(15%)和流行病学(19%)相关的性别维度。162份指南公布了其委员会主席的详细信息,其中126位(76%)是男性。由女性担任主席的委员会所制定的指南在考虑性别因素方面得分往往更高。
本研究突出了NICE指南中的关键差距,必须通过系统性的全行业进展来解决这些差距,即将按性别分类的研究纳入临床指南。作为英格兰和威尔士负责指南制定的单一焦点机构,NICE有独特的机会建立强大机制,以便将这一重要证据常规性地纳入指南。建议采取多项举措,以识别所有临床专科领域的相关现有证据。